Abstract
Use of high flow nasal therapy (HFNT) to treat COVID-19 pneumonia has been greatly debated around the world due to concern for increased healthcare worker transmission and delays in invasive mechanical Ventilation (IMV).
Methods A retrospective analysis of consecutive patients admitted to Temple University Hospital in Philadelphia, Pennsylvania, from March 10, 2020, to May 17, 2020 with moderate to severe respiratory failure treated with High Flow nasal therapy (HFNT). HFNT patients were divided into two groups: HFNT only and HFNT progressed to IMV. The primary outcome was the ability of the ROX index to predict the need of IMV.
Results Of the 837 patients with COVID-19, 129 met inclusion criteria. The mean age was 60.8 (±13.6) years, BMI 32.6 (±8), 58 (45 %) were female, 72 (55.8%) were African American, 40 (31%) Hispanic. 48 (37.2%) were smokers. Mean time to intubation was 2.5 days (± 3.3). ROX index of less than 5 at HFNT initiation was predictive of progression to IMV (OR = 2.137, p = 0,052). Any decrease in ROX index after HFNT initiation was predictive of intubation (OR= 14.67, p <0.0001). ΔROX (<=0 versus >0), peak D-dimer >4000 and admission GFR < 60 ml/min were very strongly predictive of need for IMV (ROC = 0.86, p=). Mortality was 11.2% in HFNT only group versus 47.5% in the HFNT progressed to IMV group (p,0.0001). Mortality and need for pulmonary vasodilators were higher in the HNFT progressed to IMV group.
Conclusion ROX index is a valuable, noninvasive tool to evaluate patients with moderate to severe hypoxemic respiratory failure in COVID-19 treated with HFNT. ROX helps predicts need for IMV and thus limiting morbidity and mortality associated with IMV.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was associated with this study
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Temple University Institutional Review Board (TU-IRB protocol number: 27051)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* see supplement
None of the authors have any conflict of interest related to the material
Contact Information: Maulin Patel, MD, Temple University Hospital, 7th floor Parkinson Pavilion, 3401 N Broad St, Philadelphia, PA 19140, maulin.patel{at}tuhs.temple.edu, Phone #: 2678582225
Contributions: Maulin Patel will be the corresponding author and guarantor for the manuscript. Maulin Patel, Matthew Gordon, Junad Chowdhury and Gerard J Criner formulated the overall study design. Huaqing Zhao, Nicole Patlakh, Maulin Patel, Andrew Gangemi, Robert Marron, Junad Chowdhury, Nicole Mills, Zachariah Dorey-Stein, Ibraheem Yousef, Lauren Tragesser, Julie Giurintano assisted in data collection, consolidation and analysis. Maulin Patel, Junad Chowdhury, Parth Rali, Rohit Gupta, Gilbert D’Alonzo and Matthew Gordon drafted the manuscript. Gerard J Criner and Matthew Gordon revised and reviewed the Manuscript
Data Availability
Data available upon request
